Pulse Biosciences (PLSE) Total Non-Current Liabilities (2016 - 2026)

Pulse Biosciences has reported Total Non-Current Liabilities for 11 years, with the latest figure at $16.1 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 1.9% year-over-year to $16.1 million in Q2 2026; TTM through Jun 2026 was $16.1 million, a 1.9% increase from a year earlier, with the FY2025 full-year figure at $13.9 million, down 21.11% from the prior year.
• Total Non-Current Liabilities was $16.1 million for Q2 2026 at Pulse Biosciences, up from $13.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $81.4 million in Q3 2022, with the low at $13.8 million in Q3 2023.
• Average Total Non-Current Liabilities over 5 years is $29.7 million, with a median of $16.1 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 441.6% in 2022, then tumbled 83.04% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $80.1 million in 2022, then sank by 81.54% to $14.8 million in 2023, then advanced by 18.95% to $17.6 million in 2024, then decreased by 21.11% to $13.9 million in 2025, then advanced by 15.71% to $16.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $16.1 million (Q2 2026), $13.9 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.